Clinical bottom line
Low-dose naltrexone (LDN) is emerging as a putative therapeutic option for managing persistent symptoms of Long COVID in primary care, with preliminary evidence suggesting potential benefits in symptom alleviation and quality of life improvement. However, current data remain limited and heterogeneous, warranting cautious interpretation. Clinicians should consider LDN as an experimental adjunct in select patients with refractory Long COVID symptoms, pending further rigorous validation.
What the evidence shows
Long COVID, characterized by a constellation of symptoms persisting beyond acute SARS-CoV-2 infection, poses a significant clinical challenge in primary care. Low-dose naltrexone, an opioid receptor antagonist at doses typically ranging from 1 to 5 mg daily, has been hypothesized to modulate neuroinflammation and immune dysregulation implicated in Long COVID pathophysiology.
Several recent systematic reviews and meta-analyses have synthesized emerging data on LDN for Long COVID symptom management. Du Aung et al. (2025) conducted a systematic review and meta-analysis incorporating observational studies and small clinical trials, reporting a trend toward symptom improvement, particularly fatigue, cognitive dysfunction, and pain, though effect sizes were modest and confidence intervals wide. Similarly, Byambasuren et al. (2025) found low-dose naltrexone to be associated with some symptomatic relief, but emphasized the low certainty of evidence due to study design limitations and small sample sizes.
A prospective cohort study by [Author et al.] (2025) demonstrated initial safety and tolerability of LDN in Long COVID patients, with few adverse events reported. Villatoro et al. (2026) extended these findings to pediatric and adolescent populations, noting cautious use with close monitoring.
Mechanistically, LDN’s putative benefits may derive from transient opioid receptor blockade leading to upregulation of endogenous endorphins and modulation of microglial activation, potentially mitigating neuroinflammation (Low–dose naltrexone for Long COVID, 2025). This immunomodulatory effect aligns with hypotheses of persistent immune dysregulation in Long COVID.
Caveats and uncertainty
The current evidence base is limited by small sample sizes, heterogeneous patient populations, variable dosing regimens, and lack of large randomized controlled trials. Most data derive from observational studies or open-label designs, increasing risk of bias and placebo effects. The optimal dosing, duration, and patient selection criteria for LDN in Long COVID remain undefined.
Safety data, while generally reassuring, are preliminary and require confirmation in larger cohorts, especially given the off-label use in a novel indication. Potential interactions with other medications commonly used in Long COVID management have not been extensively studied.
Furthermore, Long COVID itself is a heterogeneous syndrome with multifactorial pathogenesis; thus, LDN may benefit only specific symptom clusters or subgroups, underscoring the need for personalized approaches.
How this may change practice
While not yet standard of care, LDN may be considered as an experimental adjunctive therapy for patients with persistent, refractory Long COVID symptoms after comprehensive evaluation and exclusion of alternative diagnoses. Primary care clinicians should engage in shared decision-making, discussing the limited evidence, potential benefits, and uncertainties.
Clinicians are encouraged to monitor patients closely for efficacy and adverse effects, ideally within the context of registries or clinical studies to contribute to the growing evidence base. Referral to Long COVID specialty clinics remains important for complex cases.
Ongoing and future randomized controlled trials will be critical to establish efficacy, safety, and guidelines for LDN use in Long COVID. Until then, LDN use should be individualized and cautious.